Skip to content

Sarah Fredriksson, CEO, on Aqilion, February 16, 2023:

“The last quarter of 2022 was extremely intensive with a focus on business development and negotiations. We are therefore thrilled to report that we have reached the goal of a license agreement and an exciting collaboration with Merck.”

Aqilion is a biotech company developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions. The company is active in early phases of drug discovery, from idea stage to early clinical development.

With a carefully planned and differentiated pipeline, we have achieved the overarching goal of being able to position Aqilion as a biotech company. All our four innovative programs follow a well-defined strategy on both biological and medical grounds, as well as patient needs.


Aqilion runs four innovative R&D programs. All with focus on developing novel innovative treatments for chronic inflammatory diseases for which few or no treatments are available and where there is currently a clear patient need.


Interim Reports are distributed to shareholders only.

What we do

Research is at the heart of what we do. The Aqilion team and network has extensive expertise and experience in pursuing research to develop innovative medicines that can make a difference in the treatment of diseases in which the body’s inflammatory processes play a major role.